Copyright
©The Author(s) 2023.
World J Crit Care Med. Mar 9, 2023; 12(2): 71-88
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Published online Mar 9, 2023. doi: 10.5492/wjccm.v12.i2.71
Ref. | Study design | Population | Intervention | Outcomes |
Friesecke et al[62], 2017 | Prospective, single center study | 20 septic shock patients | CytoSorb hemoperfusion | Norepinephrinedose reduced after 6 and 12 h; Improved lactate clearance; SOFA scores unchanged; Shock reversal achieved in 65% of patients; 28-d survival – 45% |
Kogelmann et al[63], 2017 | Case series | 26 septic shock patients | CytoSorb+CVVHD | Rapid hemodynamic stabilization; Reduction in Vasopressor dose by 67%; Decrease in blood lactate by 26.4%; Shock reversal in 38.5% patients; Decreased mortality than predicted by APACHE II; No adverse events reported |
Friesecke et al[52], 2017 | International registry | 135 septic shock patients | CytoSorb hemoperfusion | Reduced observed mortality of 65% than predicted by APACHE II of 78%; Marked reduction in IL6 levels; No significant reduction in SOFA scores; Safe and well tolerated without any adverse events |
Brouwer et al[59], 2019 | Retrospective, investigator-initiated study | 116 septic shock patients | CytoSorb +CRRT | In CytoSorb group, the mean predicted mortality rate was 74.5%, while 28 d mortality rate was 47.8%; In CRRT group, the mean predicted mortality rate was 67.9%, while 28-d mortality was 51.0%; CytoSorb group was associated with a reduced 28-d mortality in comparison to CRRT (53% vs 72.3%) |
CRRT alone | ||||
Brouwer et al[60], 2021 | Long term follows up | 116 septic shock patients | CytoSorb +CRRT | CytoSorb was significantly associated with long term outcome compared to CRRT |
Retrospective cohort study | CRRT alone | |||
Mehta et al[53], 2020 | Retrospective, observational study | 40 septic shock patients | CytoSorb hemoperfusion (Survivor group vs non survivor group) | Improvement in MAP (62.82 ± 9.73mmHg); Reduction in vasopressor dose; Reduction IL-6 levels (87%) and TNF levels (24%); Decrease in SOFA scores by 16.2% |
Paul et al[68], 2021 | Prospective, real time, observational multicentre study | 45 septic shock patients | CytoSorb+ Standard therapy | 26 patients survived post therapy; Reduction in vasopressor dose (NE- 51.4%, Epinephrine – 69.4% and Vasopressin -13.9%); 52.3% reduction in IL-6 levels; Reduction in APACHE II and SOFA scores, 20.1 ± 2.47 and 9.04 ± 3.00 respectively |
(Survivor vs non survivor group) | ||||
Akil et al[69], 2020 | 20 patients with pneumogenic sepsis and ARDS | CytoSorb + Combined high flow veno-venous ECMO (CytoSorb group); ECMO therapy alone (Control group) | The 30-d mortality rate was 0% in CytoSorb group, whereas 57% was observed in control group; Significant reduction in procalcitonin and C-reactive levels were observed in CytoSorb group in comparison to control group | |
Rugg et al[61], 2020 | Retrospective single center study | 42 septic shock patients compared to 42 matched controls | Cytosorb +RRT | Catecholamines requirements decreased to 0.26 µg/kg/min within 24 h of therapy with CytoSorb; In hospital mortality was significantly lower in CytoSorb group as compared to controls (35.7% vs 61.9%); Risk factors in CytoSorb group were high lactate levels and low thrombocyte counts proior to therapy. Lactate value of 7.5 mmol/L, predicted mortality with high specificicty (88.9%) |
- Citation: Mehta Y, Paul R, Ansari AS, Banerjee T, Gunaydin S, Nassiri AA, Pappalardo F, Premužić V, Sathe P, Singh V, Vela ER. Extracorporeal blood purification strategies in sepsis and septic shock: An insight into recent advancements. World J Crit Care Med 2023; 12(2): 71-88
- URL: https://www.wjgnet.com/2220-3141/full/v12/i2/71.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v12.i2.71